These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. Gotlib J Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808 [TBL] [Abstract][Full Text] [Related]
5. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab. Schwartz LB; Sheikh J; Singh A Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes. Helbig G; Kyrcz-Krzemień S Pol Arch Med Wewn; 2011; 121(1-2):44-52. PubMed ID: 21346698 [TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Roche-Lestienne C; Lepers S; Soenen-Cornu V; Kahn JE; Laï JL; Hachulla E; Drupt F; Demarty AL; Roumier AS; Gardembas M; Dib M; Philippe N; Cambier N; Barete S; Libersa C; Bletry O; Hatron PY; Quesnel B; Rose C; Maloum K; Blanchet O; Fenaux P; Prin L; Preudhomme C Leukemia; 2005 May; 19(5):792-8. PubMed ID: 15772698 [TBL] [Abstract][Full Text] [Related]
9. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Gotlib J; Cross NC; Gilliland DG Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488 [TBL] [Abstract][Full Text] [Related]
13. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Roufosse F; Cogan E; Goldman M Allergy; 2004 Jul; 59(7):673-89. PubMed ID: 15180753 [TBL] [Abstract][Full Text] [Related]
14. Advances in diagnosis and treatment of eosinophilia. Sheikh J; Weller PF Curr Opin Hematol; 2009 Jan; 16(1):3-8. PubMed ID: 19057198 [TBL] [Abstract][Full Text] [Related]
15. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197 [TBL] [Abstract][Full Text] [Related]